Empower Your Fight Against Cholangiocarcinoma
Cholangiocarcinoma represents a complex cellular challenge. Learn about this rare illness and how protecting your living tumor tissue grants access to genomic profiling and tailored therapies that combat resistance.
Talk to a Care SpecialistWhat is Cholangiocarcinoma?
Cholangiocarcinoma, or bile duct cancer, is a rare disease forming in the slender tubes (bile ducts) that carry the digestive fluid bile through your liver. It can occur inside the liver (intrahepatic), just outside the liver (perihilar), or further downstream (distal).
Because these ducts are deeply rooted within vital organs, this cancer is exceptionally difficult to diagnose in early stages and often displays a remarkably high incidence of targetable genetic mutations when mapped properly in a laboratory.
What Does Bile Duct Cancer Do?
Tumors directly obstruct hepatic pathways, resulting in toxicity buildups that drastically impact liver function and overall health.
- Jaundice and Toxicity: Obstruction of bile flow causes yellowing of the skin and eyes, profound systemic itching, and dark urine alongside severe fatigue.
- Liver Compromise: Internal pressure and tumor expansion severely affect the liver's ability to purify blood and digest fat.
- Vascular Invasion: Operating near the hepatic artery and portal vein means surgical removals are extraordinarily delicate and complex.
Current Treatment Options
Liver Surgery
Surgical resection of the bile ducts and potentially a large section of the liver to clear the area, discarding immense amounts of biologically valuable tissue.
Systemic Treatments
Use of chemotherapies (like Gemcitabine/Cisplatin) alongside immunotherapy drugs like Durvalumab given to mitigate growth in non-surgical cases.
Biliary Drainage
Palliative mechanical interventions such as stent placements to artificially reopen blocked bile ducts and ease toxic burden.
Why Bank Your Living Bile Duct Tissue?
Over 40% of cholangiocarcinoma cases possess unique targetable genomic alterations (like FGFR2 fusions or IDH1 mutations). By cryopreserving your living tissue, you allow clinicians to model these mutations in 3D and test precision therapies off-body.
Targeted Drug Efficacy Testing
Expose living cancer structures to cutting-edge pathway inhibitors (like Pemigatinib) in an ex-vivo lab setting to guarantee efficacy before treatment.
Organoid Modeling
Cultivating your live cells constructs high-fidelity replicas of the tumors in your bile ducts, shifting trial-and-error medicine to direct empirical data.
Clinical Trial Readiness
Having fresh-frozen or fully vivified tissue maps is often mandatory for unlocking access to rapid-enrollment molecular subtype trials.
Future-Proofing Your Care
Should resistance develop against your current treatment, your banked pre-treatment biology remains untouched for re-analysis as genomic sequencing tech accelerates.